Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Advanced Cancer × apatinib × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 41 Carcinoma, Hepatocellular 38 Carcinoma, Non-Small-Cell Lung 15 Small Cell Lung Carcinoma 11 Nasopharyngeal Carcinoma 11 Colorectal Neoplasms 11 Breast Neoplasms 11 Sarcoma 10 Ovarian Neoplasms 10 Cholangiocarcinoma 10 Triple Negative Breast Neoplasms 9 Esophageal Squamous Cell Carcinoma 9 Esophageal Neoplasms 9 Lung Neoplasms 8 Advanced Gastric Cancer 7 Osteosarcoma 6 Neoplasms 6 Head and Neck Neoplasms 6 Biliary Tract Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 5 Recurrence 5 Neoplasm Metastasis 5 Liver Neoplasms 5 Uterine Cervical Neoplasms 4 Pancreatic Neoplasms 4 Glioma 4 Thyroid Neoplasms 3 Melanoma 3 Gastrointestinal Neoplasms 3 Digestive System Neoplasms 3

Interventions

Surveys and Questionnaires 7 Bevacizumab 5 temsirolimus 4 Standard of Care 4 Sirolimus 4 Interviews as Topic 4 Vorinostat 2 Paclitaxel 2 Magnetic Resonance Spectroscopy 2 Everolimus 2 Erlotinib Hydrochloride 2 Cetuximab 2 zaleplon 1 vistusertib 1 tilsotolimod 1 pazopanib 1 olaparib 1 liposomal doxorubicin 1 capivasertib 1 apatinib 1 Videotape Recording 1 Vemurafenib 1 Valproic Acid 1 Trastuzumab 1 Topotecan 1 Temozolomide 1 Sunitinib 1 Sorafenib 1 Rehabilitation 1 Referral and Consultation 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03645200 2019-04-25

Treatment of Carrying TP53 Harmful Mutations

Tianjin Medical University Second Hospital

Phase 1 Unknown

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡